Canadian Cell & Gene Therapy Strategy Workshop

Pre-Conference Workshop
Wednesday, May 2
08:30 - 16:15

Learn about the landscape of regenerative medicine in Canada and maximizing the opportunities identified by the Canadian Council of Academies 2016 Report: Building on Canada’s Strength in Regenerative Medicine. Organized by CellCAN, this workshop will feature presentations and panel discussions with global speakers on cell and gene therapy manufacturing structure, and investment and economic feasibility of cell and gene therapy treatments in Canada.

Moderator:

Michel Rochon, former Science Journalist at the Canadian Broadcasting Corporation (CBC), Montreal, Canada

Supporters

Program Information

Chair:

Armand Keating, MD, Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation, University of Toronto, Canada

Speakers:

Denis-Claude Roy, MD, PhD, CEO, CellCAN, Montreal, Canada
Oumeya Adjali, MD, PhD, Directrice du laboratoire de thérapie génique de Nantes, Unité de thérapie cellulaire et génique du CHU de Nantes, Nantes, France
John Rasko, MD, PhD, ISCT President-Elect, Professor of Medicine, Central Clinical School, Centenary Institute of Cancer Medicine& Cell Biology, Sydney, Australia
Isabelle Rivière, PhD, Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Centre, New York, United States

Coordinating clinical needs with manufacturing capabilities requires a vast knowledge of existing infrastructure and a clear vision of the direction for future expansion. In this session, the current cell and gene therapy manufacturing facilities landscape will be reviewed, contrasting academic vs. private centers, production capacity for multicenter clinical trials, centralized vs. decentralized manufacturing, sustainability of current infrastructure and maximizing output will be discussed. The landscape in Canada, France, Australia and the United States will be compared to identify strengths and opportunities.

Chair:

Michael May, PhD, President & Chief Executive Officer, Center for Commercialization of Regenerative Medicine, Toronto, Canada

Speakers:

Aaron Dulgar-Tulloch, PhD, Director, BridGE, GE Healthcare, Toronto, Canada
Robert Deans, PhD, Chief Technology Officer, BlueRock Therapeutics, Toronto, Canada
Frank Van Lier, PhD, Director R&D, Bioprocess Engineering, Life Sciences, Human Health Therapeutics, National Research Council Canada, Montreal, Canada

In this session, strategic opportunities that exist for industry to invest in cell & gene therapy infrastructure in Canada will be discussed. How industry investment in Canadian GMP manufacturing facilities strengthens marketing and visibility, the impact of industry-driven later-phase clinical trial and commercialization will be reviewed.

Chair:

Lambert Busque, MD, Chief Medical Officer, Center for the Commercialization of Cancer Immunotherapy, Montreal, Canada

Speakers:

Kelly Robinson, MSc, Director, Centre for Evaluation of Radiopharmaceuticals & Biotherapeutics, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada
Nick Crabb, PhD, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence, London, United Kingdom
Richard Maziarz, MD, Professor of Medicine, Oregon Health & Science University, Chair, Interest Group for ASBMT on Value and Health Economics, Portland, United States

Innovative cellular therapies are disruptive technologies to healthcare and require adequate foresight in drafting novel reimbursement policies. In this session, cell & gene therapies, such as viral vector-based gene therapies involving cells, hematopoietic stem cell transplantation, CAR-T cell therapy, and cancer immunotherapy will be discussed in the context of regulatory policy, patient access and novel reimbursement strategies. Should private or public insurance pay?

Speakers:

Michael Rudnicki, PhD, Chair, Regenerative Medicine Alliance of Canada, Scientific Director, Stem Cell Network, Ottawa, Canada
Erika Kleiderman, BSc, LLB, Academic Associate, Centre of Genomics and Policy, McGill University, Montreal, Canada
Dina Iezzi, Director, Marketing & Special Projects Therapure Biopharma Inc, Toronto, Canada
Duncan Stewart, MD, President and Scientific Director, Ontario Institute for Regenerative Medicine, Ottawa, Canada

Stem Cell research was pioneered in Canada in the early 60s and ever since Canada’s contribution to regenerative medicine has been unwavering. Today, this emerging Canadian sector has taken hold. In partnership with government, industry and others, Canada is well positioned to realize a robust and globally competitive sector. This session will look at Canada’s regenerative medicine ecosystem in an effort to better understand where the opportunities lie.

To view full meeting program, please refer to the program schedule.

Confirmed Speakers

Oumeya Adjali, MD, PhD, Directrice du laboratoire de thérapie génique de Nantes, Unité de thérapie cellulaire et génique du CHU de Nantes, Nantes, France
Nick Crabb, PhD, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence, London, United Kingdom
Robert Deans, PhD, Chief Technology Officer, BlueRock Therapeutics, Toronto, Canada
Aaron Dulgar-Tulloch, PhD, Director, BridGE, GE Healthcare, Toronto, Canada
Dina Iezzi, Director, Marketing & Special Projects Therapure Biopharma Inc, Toronto, Canada
Erika Kleiderman, BSc, LLB, Academic Associate, Centre of Genomics and Policy, McGill University, Montreal, Canada
Frank Van Lier, PhD, Director R&D, Bioprocess Engineering, Life Sciences, Human Health Therapeutics, National Research Council Canada, Montreal, Canada
Richard Maziarz, MD, Professor of Medicine, Oregon Health & Science University, Chair, Interest Group for ASBMT on Value and Health Economics, Portland, United States
John Rasko, MD, PhD, ISCT President-Elect, Professor of Medicine, Central Clinical School, Centenary Institute of Cancer Medicine& Cell Biology, Sydney, Australia
Isabelle Rivière, PhD, Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Centre, New York, United States
Kelly Robinson, MSc, Director, Centre for Evaluation of Radiopharmaceuticals & Biotherapeutics, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada
Denis-Claude Roy, MD, PhD, CEO, CellCAN, Montreal, Canada
Michael Rudnicki, PhD, Chair, Regenerative Medicine Alliance of Canada, Scientific Director, Stem Cell Network, Ottawa, Canada
Duncan Stewart, MD, President and Scientific Director, Ontario Institute for Regenerative Medicine, Ottawa, Canada

Organizing Committee

Denis-Claude Roy, MD, FRCPC, Chief Executive Officer, CellCAN, Canada – Co-Chair
Craig Hasilo, Chief Scientific Officer, CellCAN, Canada – Co-Chair

Frank Van Lier, Director R&D, Bioprocess Engineering, Life Sciences – Human Health Therapeutics, National Research Council Canada
Friedericke Pfau, Chargée de projets LOEX, CMDGT
Sandra Donaldson, Vice President & Chief Operating Officer, Ontario Institute for Regenerative Medicine
Cate Murray, Executive Director & Chief Operating Officer, Stem Cell Network
Michel Tremblay, James McGill Professor, McGill University
Julie Fradette, Directrice, ThéCell
Amanda MacDonald, Executive Director, BC RegMed
Stephanie Michaud, President & Chief Executive Officer, BioCANRx
Patrick Bedford, Senior Manager, Clinical Translation & Regulatory Affairs, Centre for Commercialization of Regenerative Medicine
Rénée Bazin, Directeur, Innovation, Affaires Médicales et Innovation, Héma-Québec
Jodi Garner, Senior Manager, Science and Industry Relations, Ontario Institute for Regenerative Medicine
Louisa Petropoulos, Director, Business Development and Operations, Centre for Commercialisation of Cancer Immunotherapy (C3i)
Vanessa Laflamme, Chief Operating Officer, CellCAN Regenerative Medicine and Cell Therapy Network